Abstract
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China. Rapidly evolving technology in molecular biology such as high-throughput sequencing and integrative analysis of genomic and transcriptomic landscapes have enabled the identification of key oncogenic events for prostate cancer initiation, progression and resistance to hormonal therapy. These surging data of prostate cancer genome also provide insights on ethnic variation and the differences in histological subtype of this disease. In this review, differences in the incidence of prostate cancer and the prevalence of main genetic alterations between Asian and Western populations are discussed. We also review the recent findings on the mechanisms underlying neuroendocrine differentiation of prostate cancer and the development of small cell neuroendocrine carcinoma after androgen deprivation therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61: 69–90
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63: 11–30
Center M M, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol, 2012, 61: 1079–1092
Kimura T. East meets west: ethnic differences in prostate cancer epidemiology between east asians and caucasians. Chin J Cancer, 2012, 31: 421–429
Eeles R A, Olama A A, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the icogs custom genotyping array. Nat Genet, 2013, 45: 385–391
Goh C L, Schumacher F R, Easton D, et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med, 2012, 271: 353–365
Xu J, Mo Z, Ye D, et al. Genome-wide association study in chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet, 2012, 44: 1231–1235
Ewing C M, Ray A M, Lange E M, et al. Germline mutations in hoxb13 and prostate-cancer risk. N Engl J Med, 2012, 366: 141–149
Lin X, Qu L, Chen Z, et al. A novel germline mutation in hoxb13 is associated with prostate cancer risk in Chinese men. Prostate, 2013, 73: 169–175
Economides K D, Capecchi M R. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development, 2003, 130: 2061–2069
Miao J, Wang Z, Provencher H, et al. Hoxb13 promotes ovarian cancer progression. Proc Natl Acad Sci USA, 2007, 104: 17093–17098
Kim Y R, Oh K J, Park R Y, et al. Hoxb13 promotes androgen independent growth of lncap prostate cancer cells by the activation of E2F signaling. Mol Cancer, 2010, 9: 124
Norris J D, Chang C Y, Wittmann B M, et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell, 2009, 36: 405–416
Barbieri C E, Baca S C, Lawrence M S, et al. Exome sequencing identifies recurrent spop, FOXA1 and MED12 mutations in prostate cancer. Nat Genet, 2012, 44: 685–689
Geng C, He B, Xu L, et al. Prostate cancer-associated mutations in speckle-type poz protein (spop) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci USA, 2013, 110: 6997–7002
Tomlins S A, Rhodes D R, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 2005, 310: 644–648
Rubin M A, Maher C A, Chinnaiyan A M. Common gene rearran-gements in prostate cancer. J Clin Oncol, 2011, 29: 3659–3668
Kumar-Sinha C, Tomlins S A, Chinnaiyan A M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer, 2008, 8: 497–511
Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate, 2011, 71: 489–497
Rosen P, Pfister D, Young D, et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology, 2012, 80: 749–753
Ren S, Peng Z, Mao J H, et al. RNA-Seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res, 2012, 22: 806–821
Xue L, Mao X, Ren G, et al. Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status. Am J Cancer Res, 2012, 2: 736–744
Lee K, Chae J Y, Kwak C, et al. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology, 2010, 76: 1268.e7–13
Mao X, Yu Y, Boyd L K, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res, 2010, 70: 5207–5212
Konishi N, Hiasa Y, Tsuzuki T, et al. Comparison of Ras activation in prostate carcinoma in Japanese and American men. Prostate, 1997, 30: 53–57
Cho N Y, Choi M, Kim B H, et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer, 2006, 119: 1858–1862
Shen Y, Lu Y, Yin X, et al. KRAS and BRAF mutations in prostate carcinomas of Chinese patients. Cancer Genet Cytogenet, 2010, 198: 35–39
Ren G, Liu X, Mao X, et al. Identification of frequent BRAF copy number gain and alterations of raf genes in Chinese prostate cancer. Genes Chromosomes Cancer, 2012, 51: 1014–1023
Shiraishi T, Muneyuki T, Fukutome K, et al. Mutations of Ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. Anticancer Res, 1998, 18: 2789–2792
Yoshimoto M, Cutz J C, Nuin P A, et al. Interphase fish analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet, 2006, 169: 128–137
Taylor B S, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell, 2010, 18: 11–22
Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 2003, 4: 209–221
Kollermann J, Albrecht H, Schlomm T, et al. Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncol Lett, 2010, 1: 729–732
Zong Y, Goldstein A S. Adaptation or selection—mechanisms of castration-resistant prostate cancer. Nat Rev Urol, 2013, 10: 90–98
Grasso C S, Wu Y M, Robinson D R, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487: 239–243
Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res, 2009, 1: 148–162
Beltran H, Tagawa S T, Park K, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol, 2012, 30: e386–389
Li Z, Chen C J, Wang J K, et al. Neuroendocrine differentiation of prostate cancer. Asian J Androl, 2013, 15: 328–332
Goldstein A S, Stoyanova T, Witte O N. Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol, 2010, 4: 385–396
Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl, 1998, 8: 18–22
Huang J, Yao J L, di Sant’Agnese P A, et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate, 2006, 66: 1399–1406
Kyprianou N, Isaacs J T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 1988, 122: 552–562
Abrahamsson P A, Wadstrom L B, Alumets J, et al. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract, 1987, 182: 298–307
Beltran H, Rickman D S, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov, 2011, 1: 487–495
Hirano D, Okada Y, Minei S, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol, 2004, 45: 586–592
Germann M, Wetterwald A, Guzman-Ramirez N, et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells, 2012, 30: 1076–1086
Lee L F, Guan J, Qiu Y, et al. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol, 2001, 21: 8385–8397
Goldstein A S, Lawson D A, Cheng D, et al. TROP2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA, 2008, 105: 20882–20887
Leong K G, Wang B E, Johnson L, et al. Generation of a prostate from a single adult stem cell. Nature, 2008, 456: 804–808
Wang X, Kruithof-de Julio M, Economides K D, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature, 2009, 461: 495–500
Burchardt T, Burchardt M, Chen M W, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol, 1999, 162: 1800–1805
Yuan T C, Veeramani S, Lin F F, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive lncap cells. Endocr Relat Cancer, 2006, 13: 151–167
Deeble P D, Murphy D J, Parsons S J, et al. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol, 2001, 21: 8471–8482
Bang Y J, Pirnia F, Fang W G, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA, 1994, 91: 5330–5334
Kim J, Adam R M, Freeman M R. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res, 2002, 62: 1549–1554
Lapuk A V, Wu C, Wyatt A W, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol, 2012, 227: 286–297
Papandreou C N, Daliani D D, Thall P F, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol, 2002, 20: 3072–3080
Flechon A, Pouessel D, Ferlay C, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the french genito-urinary tumor group (GETUG) P01 trial. Ann Oncol, 2011, 22: 2476–2481
Lee L F, Louie M C, Desai S J, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene, 2004, 23: 2197–2205
Huang J, Yao J L, Zhang L, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol, 2005, 166: 1807–1815
Acosta J C, O’Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell, 2008, 133: 1006–1018
Chen H, Sun Y, Wu C, et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the p53 pathway. Endocr Relat Cancer, 2012, 19: 321–331
Greenberg N M, DeMayo F, Finegold M J, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA, 1995, 92: 3439–3443
Gingrich J R, Barrios R J, Morton R A, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res, 1996, 56: 4096–4102
Chiaverotti T, Couto S S, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol, 2008, 172: 236–246
Ahuja D, Saenz-Robles M T, Pipas J M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene, 2005, 24: 7729–7745
Zhou Z, Flesken-Nikitin A, Corney D C, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res, 2006, 66: 7889–7898
Xin L, Ide H, Kim Y, et al. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci USA, 2003, 100(Suppl 1): 11896–11903
Xin L, Teitell M A, Lawson D A, et al. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA, 2006, 103: 7789–7794
Zong Y, Xin L, Goldstein A S, et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA, 2009, 106: 12465–12470
Memarzadeh S, Xin L, Mulholland D J, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell, 2007, 12: 572–585
Lawson D A, Zong Y, Memarzadeh S, et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA, 2010, 107: 2610–2615
Zong Y, Huang J, Sankarasharma D, et al. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci USA, 2012, 109: E3395–3404
Goldstein A S, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science, 2010, 329: 568–571
Goldstein A S, Drake J M, Burnes D L, et al. Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc, 2011, 6: 656–667
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Biographical Sketch Dr. Huang JiaoTi grew up in a small town near Hefei, Anhui Province and attended Anhui Medical University 1978–1983. He studied at the Academy of Military Medical Sciences in Beijing in 1983 and obtained Master’s degree in 1986. He was in the CUSBEA Class VI (1987) and earned his Ph.D. from New York University School of Medicine in 1991. He then did postdoctoral research at NYU and Yale. He did residency training in pathology at NYU School of Medicine 1995–1999 and a fellowship in Oncologic Pathology at Memorial Sloan-Kettering Cancer Center 1999–2000. He worked at the University of Rochester starting 2000 and rose to the rank of Professor in 2007. He moved to UCLA in 2008 and is currently Professor of Pathology and Urology and Director of Urologic Pathology. Dr. Huang has medical licenses from New York and California. His clinical interest is in the pathologic diagnosis of cancers of the prostate, bladder, kidney, testis and adrenal glands. His research laboratory has been studying the molecular mechanisms, biomarkers and novel therapies for advanced prostate cancer. His research has been supported by the National Institute of Health, Department of Defense Prostate Cancer Research Program, American Cancer Society, Prostate Cancer Foundation (PCF) and Stand Up to Cancer Dream Team award. In addition to his work in the United States, Dr. Huang travels to China regularly to lecture and for collaborative research. He is a co-Chair of PCF-China initiative and has successfully organized the annual PCF-China Scientific Symposium in 2012 and 2013. His lab has trained many urologists and other clinicians from various institutions in China.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Zong, Y., Goldstein, A.S. & Huang, J. The molecular basis for ethnic variation and histological subtype differences in prostate cancer. Sci. China Life Sci. 56, 780–787 (2013). https://doi.org/10.1007/s11427-013-4522-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-013-4522-0